Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Varsha Gandhi, PhD, on Ibrutinib

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Aug

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Varsha Gandhi, PhD, on Ibrutinib

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Early Trial Supports KRAS Vaccine Strategy for Pancreatic Cancer Interception

All-Oral Combination of Revumenib, Decitabine/Cedazuridine, and Venetoclax for Relapsed or Refractory AML

New Data on 14- vs 28-Day Venetoclax/Azacitidine in AML

Fusobacterium Positivity Predicts Relapse Risk and Limited Benefit From Adjuvant Chemotherapy in Colorectal Cancer

Durvalumab Plus Radiation Therapy in Frail Patients With Locally Advanced NSCLC